Ozempic Costs Across Federal Programs, Compared

Last updated 3 hours ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.

Someone shopping for Ozempic can find a Medicare price, a VA copay table and a cash offer that seem to describe the same medicine. They do not describe the same bill. Federal programs cover and pay for Ozempic under different rules; some posted figures are not patient prices at all.

Even when a patient can use more than one route, the cheapest number on a page may not apply to their pen or tablet, dose or pharmacy. A cash purchase may also leave the insurance spending limit untouched. The useful comparison is what the same prescription costs under each route the patient can actually use.

Why these prices are not interchangeable

The Food and Drug Administration’s Ozempic tablet label describes a once-daily pill for adults with type 2 diabetes, including a cardiovascular-risk indication. The agency’s injection label describes a different Ozempic product, with type 2 diabetes, cardiovascular and kidney-risk indications. A prescription for one form does not establish that a plan will cover the other, and a price for one strength need not apply to another.

Novo Nordisk defines a list price as the manufacturer’s price before discounts or rebates. The manufacturer says the amount a patient pays depends on insurance coverage. A federal purchaser’s price, an insurer’s allowed price, an advertised cash price and a person’s copay answer different questions.

The Centers for Medicare & Medicaid Services (CMS) lists Ozempic, Rybelsus and Wegovy together at $274 for a 30-day supply in its 2027 Medicare negotiation fact sheet. A separate CMS example gives $276.78 for one specified Ozempic pen package under that future maximum fair price. The figures differ because one is a group-level 30-day figure and the other is a package example; neither is a patient-specific quote.

Medicare calls Part D its prescription drug coverage. HealthCare.gov calls a plan’s covered-drug list its formulary. The Department of Veterans Affairs (VA) posts its 2026 copay rates. Federal Employees Health Benefits (FEHB) plans have their own formularies and costs rather than one federal pharmacy price.

The tablet label cautions that Ozempic and Rybelsus tablets are not interchangeable milligram for milligram. It directs patients to take an oral dose once daily. That regimen is different from an injection, so a cost comparison should start with the actual prescription rather than the shared semaglutide ingredient. The pill and pen also have different listed strengths; an offer for a pen starting dose cannot be used to price a month of tablets.

Medicare: negotiated price versus the pharmacy bill

Medicare says Part D drug costs depend on the plan selected. Plans may use prior authorization, step therapy and quantity limits. A beneficiary therefore needs the precise Ozempic product on the plan’s current drug list, not just a statement that Medicare covers prescription drugs.

For 2026, a Part D plan’s deductible cannot exceed $615, although some plans have no deductible. Medicare’s 2026 annual out-of-pocket threshold is $2,100 for covered Part D drugs, counting certain payments made on a beneficiary’s behalf. The deductible and annual limit describe different stages of coverage; neither turns the future $274 negotiated amount into a flat copay.

CMS says its negotiated prices will be effective January 1, 2027. Until then, an estimate must use the existing plan’s 2026 terms. Medicare’s plan comparison lets a person compare estimated monthly and yearly costs. It also advises checking whether the plan covers the prescriptions and includes the pharmacy.

Medicare defines prior authorization as plan approval obtained by the patient or prescriber before certain drugs are covered. It says plans may require proof that a medicine is medically necessary and meets plan conditions, including coverage for particular diagnoses. When coverage begins, a plan may offer a one-time 30-day transition fill for a medicine that is not on its list or still needs authorization. That temporary supply is a bridge, not a guarantee of continuing coverage; ask the plan what must happen before the next refill.

CMS lists Wegovy, Zepbound and Foundayo for its weight-management Bridge, not Ozempic. It says a beneficiary with type 2 diabetes is ineligible for that Bridge, even if a Part D plan does not cover a GLP-1 for that condition. A patient cannot use the Bridge’s weight-management price as an Ozempic quote; whether the plan pays for a particular prescription still depends on its drug list and approval rules.

Medicaid: state rules determine the answer

All states provide outpatient prescription coverage to categorically eligible Medicaid enrollees and most other enrollees. That broad coverage is not a promise that every Ozempic form or use is covered without conditions. Federal Medicaid rules allow state cost sharing that varies with income, while exempting some groups and services.

The Medicaid Drug Rebate Program offsets federal and state program spending. A rebate changes the payer’s economics; it does not supply a national Ozempic copay for a patient. CMS publishes state prescription-drug resources describing each state’s coverage and reimbursement methods. For an actual amount, a beneficiary needs their state’s or managed-care plan’s drug list, authorization rules and pharmacy information.

Medicaid’s federal cost-sharing rules generally keep charges nominal for low-income enrollees. They exempt children, terminally ill people and residents of institutions from many out-of-pocket charges. A household should not assume a copay quoted by someone in another state or eligibility group applies to its own prescription. A state-specific formulary check matters as much as the posted copay.

VA and TRICARE: different eligibility and pharmacy routes

A VA Pharmacy Benefits Management decision from April 2026 lists updated Ozempic injection criteria for type 2 diabetes. That document does not establish an Ozempic pill benefit or a single veteran price. VA says its 2026 copay obligation can vary by disability rating, income and eligibility.

For veterans who owe medication copays, VA’s table lists $11 for a 1-to-30-day tier-three brand-name supply, with lower amounts for other tiers and a $700 annual medication-copay cap. The tier assigned to a particular approved prescription has to be checked with VA; the published table alone does not price Ozempic.

TRICARE’s 2026 guidance says it covers Ozempic for type 2 diabetes subject to clinical criteria and provider paperwork. That guidance does not settle whether every pen and pill strength has the same formulary status. TRICARE’s current formulary page says it reviews the formulary each quarter and provides a drug lookup.

Its pharmacy table lists no copay for covered formulary drugs at military pharmacies, with different charges for home delivery and network retail fills for many beneficiaries. A TRICARE member should check the drug category and personal beneficiary group before reading a row of that table as their own price.

TRICARE’s pharmacy table compares up to 90 days at a military or home-delivery pharmacy with up to 30 days at a retail network pharmacy. The different supply lengths make a raw comparison of the listed copays misleading. For a refill, compare the number of days, the Ozempic form and the pharmacy channel together, and confirm whether authorization has been approved.

Federal employee and Marketplace coverage

The Office of Personnel Management’s FEHB carrier guidance permits different formularies, tiers, copays and authorization rules between plan options. There is no national FEHB Ozempic copay to quote. A federal employee needs their own plan’s current formulary and benefit brochure, then an estimate for the prescribed form and pharmacy.

HealthCare.gov tells Marketplace enrollees to check the insurer’s drug formulary and Summary of Benefits and Coverage. A Marketplace plan’s total cost includes premium, deductible, copays or coinsurance, and an out-of-pocket maximum. A low monthly premium alone cannot tell a shopper whether an Ozempic prescription is affordable over a year.

HealthCare.gov says plans can require an in-network pharmacy. If an insurer denies a request for a coverage exception, a patient may appeal the decision. Before switching plans or paying cash, check the exact pen or tablet, its formulary tier, any authorization requirement and the participating pharmacy.

HealthCare.gov tells patients to check whether their pharmacy is in network. An out-of-network fill or unresolved denial can make the first insurance quote look worse than the plan’s final covered cost.

TrumpRx: the cash offer and its limits

The TrumpRx Ozempic pen page advertises $199 for each of two introductory monthly fills at 0.25 or 0.5 milligrams for eligible new self-pay patients through Dec. 31, 2026. It lists $349 per month for later 0.25, 0.5 or 1 milligram fills and $499 for 2 milligrams. The pen page directs an eligible shopper to present its coupon at the pharmacy. A patient already on the medicine, on a different dose, or filling after the offer window cannot assume the starter figure.

Novo Nordisk’s Ozempic price page lists pill self-pay prices of $149, $199 and $299 for 1.5, 4 and 9 milligrams, respectively, per 30-tablet month. Those are pill prices, not a single price for the injection or a guaranteed insured copay.

The pill page calls its self-pay price dose-dependent and defines a month as one bottle of 30 tablets. The pill offer asks for a valid prescription and a coupon presented at the pharmacy. Compare a 30-tablet pill bottle with a one-month pen fill by the prescribed regimen, not by the product name alone.

Novo Nordisk says Medicare Part D beneficiaries may use a self-pay route outside their coverage but cannot use its commercially insured $25 savings offer. It says Medicaid beneficiaries may also use a self-pay route outside their coverage. The exclusion on the commercial savings card must not be mistaken for a blanket ban on self-pay; the offer terms and the covered cost are separate checks.

The pen offer’s terms say the self-pay purchase cannot be reimbursed by insurance and cannot count toward the deductible or out-of-pocket limit. Someone with a government program should check the precise offer’s eligibility before relying on a cash figure; someone with coverage should compare the covered price and the cash price separately.

Get a price that applies to the prescription

HealthCare.gov advises a shopper to compare the plan’s price with the TrumpRx cash price. Start with the clinician’s exact product, form, strength, dose and reason for prescribing; a plan may evaluate a different use differently. Then check the relevant plan or program’s live formulary, authorization rules, pharmacy network and estimated cost for that prescription.

A Medicare enrollee can use Medicare’s plan comparison to estimate annual drug cost. A Medicaid enrollee can start with the state prescription-drug resources. A TRICARE beneficiary can check the current TRICARE formulary. A Marketplace enrollee can use the insurer’s drug list and benefits summary. VA patients and federal employees need their own care team or plan, because those systems do not produce a universal Ozempic quote.

Ask the pharmacist to compare the covered claim with any eligible cash offer before filling, and ask which payment will count toward the applicable spending limit. The pen’s introductory cash terms are time-limited. Medicare’s negotiated group price begins in 2027. Those two dates make a later recheck worthwhile, but neither changes today’s plan-specific bill.

Our articles make government information more accessible. Please consult a qualified professional for financial, legal, or health advice specific to your circumstances.